A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN17092, an Anti-SARS-CoV-2 (COVID-19) Monoclonal Antibody, in Adult Healthy Volunteers
Latest Information Update: 31 Mar 2025
At a glance
- Drugs REGN 17092 (Primary) ; REGN 17092 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 27 Mar 2025 Status changed from active, no longer recruiting to completed.
- 11 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2023 Status changed from not yet recruiting to recruiting.